Management of Toxicities with Targeted Therapies for Breast Cancer
Staying up-to-date with the available treatment options is important to clinicians integrating new evidence-based data into their clinical practice, and being familiar with their toxicity profiles is important to optimize patient outcomes.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Practical Application of Immuno-Oncology in Renal Cell Carcinoma
The goal of this activity is to improve participants’ competence in and performance at applying practice-changing clinical data, expert recommendations, and guidelines to optimize the use of immuno-oncology–based combinations in the care of their patients with RCC.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Multiple Myeloma
Discussing specific patient cases, providing the rationale for the treatment choices based on expert experience and recent data from trials, and outlining strategies to provide adequate supportive care will assist clinicians treating transplant ineligible and elderly patients with multiple myeloma in making optimal treatment decisions and improving patient outcomes.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Lung Cancer
For each of the emerging therapies described (bevacizumab, PARP inhibitors, and HIPEC), the treatment settings, patient selection criteria, and other therapies used in conjunction have varied widely across clinical trials. This has led to much discussion and likely confusion regarding the exact clinical contexts in which these new options should be considered.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Molecular Testing Updates and Impact for Clinical Practice
Identification of new genetic alterations and targeted therapies has led to an accompanying increase in the numbers of conditions that require testing in cancer patients.
Category
  • Diagnostics
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Recognition and Management of Graft Versus Host Disease
Graft versus host disease (GVHD) is a serious complication that increases mortality and significantly impacts quality of life in allogeneic HCT recipients.  A thorough understanding of the various clinical manifestations of acute and chronic GVHD is essential for the early recognition of signs and symptoms. Oncology nurses require ongoing education that provides expert guidance necessary for the optimal management of patients with GVHD.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Practical Use of Next Generation Sequencing in Metastatic Disease
Next generation sequencing methods are increasingly being utilized to match patients with targeted therapies.
Category
  • Diagnostics
Format
  • Enduring Activity
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Treatment Considerations in Older Adult Oncology
As the population ages, treatment considerations in older adult patients with cancer become relevant for all specialties. Proper selection of patients is the key to administering effective and safe cancer treatment, including knowing which patients should receive supportive care earlier.
Category
  • Senior Adult Oncology
Format
  • Enduring Activity
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Immune Checkpoint Inhibitor Toxicities
Practical knowledge and skills are required to manage the needs of the growing patient population treated with ICIs, particularly as our understanding of best practices for addressing complex toxicities evolves.
Category
  • Management of Immunotherapy-Related Toxicities
Format
  • Enduring Activity
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
The Role of Biosimilars in Cancer Treatment
Challenges remain in the acceptance of biosimilars by physicians, payers and patients in the U.S., similar to those faced by generic drugs when they were first introduced to the market. Increased education and awareness of the FDA-approval process for biosimilars and increased understanding of the evidence required to demonstrate their safety and efficacy will help to close this practice gap and ensure the acceptance and use of biosimilars in clinical practice.
Category
  • Biosimilars
Format
  • Enduring Activity
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages